- Case report
- Open Access
Congenital Afibrinogenemia presenting as antenatal intracranial bleed: a case report
© Hariharan et al; licensee BioMed Central Ltd. 2010
Received: 3 March 2009
Accepted: 5 January 2010
Published: 5 January 2010
Congenital afibrinogenemia is a very rare inherited coagulation disorder, characterized by virtual absence of plasma fibrinogen (factor I). There are only about 250 cases reported in the world literature . We describe a case of congenital afibrinogenemia which presented as an antenatally detected intracranial bleed.
Baby was born by elective lower segment caesarean section for fetal indication in view of possible uncal coning. Baby was intubated and ventilated at birth due to poor respiratory efforts.
On clinical examination, she had a large head with wide fontanel. Otherwise clinical examination was unremarkable. There was no obvious external congenital malformations. There was no obvious external bleeding tendency.
A detailed blood investigation was done to identify the cause. Hemoglobin done at birth was 8.2 mg/dL. C reactive protein, total count, differential count and micro ESR done did not suggest sepsis. Blood culture was reported sterile. PT and APTT done on second day of life was both significantly prolonged. The initial INR was also prolonged (6.36). Platelet count was 1.3 lakhs/cmm.
The various possibilities for bleeding diathesis were considered and evaluated. Disseminated intravascular coagulation and sepsis was ruled out as sepsis work was reported negative and platelet count was normal. The possibility of a coagulation disorder was considered in view of the clinical profile and abnormal coagulation profile. A fibrinogen level was done to rule out the possibility of afibrinogenemia which was reported to be undetectable. In view of the prolonged INR and APTT along with an undetectable Fibrinogen level, the diagnosis of Congenital afibrinogenemia was made.
Baby was managed with Cryoprecipitates. Packed cell transfusion was given in view of low hemoglobin value initially. The fibrinogen activity was 64 on day 2 of life following one infusion of cryoprecipitate. Values above 100 was achieved by 9 days of life and was maintained so with alternate days of cryoprecipitate infusion. The INR and coagulation profile transiently improved with cryoprecipitate, to subsequently revert to the previous prolonged state when stopped. The decision was made to maintain fibrinogen activity above 100 mg/dL (Normal value - 200 to 400 mg/dL).
2 subdural taps were done on first and third days respectively which drained liquefied blood. Ophthalmology consultation on day 2 of life showed pale disc with pale retina
Baby was ventilated for a total of 14 days and extubated once clinical condition stabilized. Cryoprecipitate was stopped from 22nd day of life to see the magnitude of fall in fibrinogen activity. On 25th day of life, Fibrinogen level was detected to be 45 mg/dL. A repeat neurosonogram on 25th day of life showed persistence of subdural hematoma with pressure effect. There was probably a fresh episode of bleeding associated with significant mass effect. Supportive measures was given including cryoprecipitate with which the child clinically improved.
Congenital afibrinogenemia is transmitted by an autosomal recessive gene located on chromosome 4 (q26-q28). Partial deficiency of fibrinogen is called hypofibrinogenemia and is a milder disorder. Afibrinogenemia occurs in the homozygous state while hypofibrinogenemia in heterozygotes . Congenital absence of fibrinogen (Afibrinogenemia) was first described in 1920 and has an estimated incidence of 1: 1-2,000,000 .
Congenital afibrinogenemia patients may present with bleeding in the newborn period manifesting as hematomas from traumatic delivery. They may also present with hemetemesis, malena or bleeding from the umbilicus. Other manifestations include bleeding in soft tissues, mucosa and following circumcision. Despite having totally incoagulable blood, these patients normally do not have severe spontaneous bleeding, but the case identification is important to prevent more severe bleeding following injuries or surgery . Intracranial hemorrhage is a rare presentation of the condition in a neonate. Antenatal detection of intracranial bleed is still a rarer entity. Intracranial hemorrhage has been described as a frequent cause of death in this disorder [5–7].
As it is a disorder with the final substrate for formation of the clot missing, results of all screening tests such as clotting time, PT, PTT and thrombin time are abnormal. Platelet functions such as bleeding time, adhesion and aggregation may also be abnormal. Diagnosis is evident by standard fibrinogen assays.
Afibrinogenemic patients have undetectable or nearly undetectable levels of fibrinogen (<10 mg/dL; normal 200-400 mg/dL) by activity-based clotting assays and by measurement of immunoreactive fibrinogen. In the absence of consumptive coagulopathy, an unmeasurable fibrinogen level is diagnostic of the condition . Hemorrhagic symptoms in fibrinogen deficiency are most significant when the plasma level is less than 50 mg/dl [8, 9]. Fresh bleeding was noticed in our case, when the fibrinogen fell to 45 mg/dL.
Acute hemorrhagic episodes can be treated with either fresh frozen plasma or cryoprecipitate or fibrinogen concentrate (Cohn fraction I). Each cryoprecipitate bag contains 100 to 150 mg of fibrinogen, and therapy with 100 mg/kg of fibrinogen provides a hemostatic plasma level. The half-life of fibrinogen is 2-4 days and frequent infusions are usually not necessary. However, our patient required frequent transfusions. There was fresh bleeding detected on ultrasonography when cryoprecipitate was stopped temporarily. Recommendations regarding target levels for treating bleeding range from 30-50 mg/dL  to 100 mg/dL .
Although prophylactic treatment with regular infusions of cryoprecipitate has been advocated by some,  it is not recommended by others for several reasons. This is based on the fact that spontaneous bleeding is very rare and mild. Moreover, there is a potential danger of acquiring infections with regular blood product infusion. Antibodies have been reported to form against fibrinogen with resultant thromboembolic complications, particularly pulmonary embolism
Acquired hypofibrinogenemia is common in disseminated intravascular coagulation and primary fibrinolysis. The possibility of acquired afibrinogenemia is unlikely in our case due to its antenatal presentation. A detailed sepsis screen done was unremarkable.
The incidence of spontaneous abortions is high in afibrinogenemic and hypofibrinogenemic females [13–15]. Prepartum and postpartum bleeding are relatively common, and intraabdominal bleeding from ruptured corpus luteal cysts have been reported. We had explained regarding a detailed evaluation of the mother for any Fibrinogen disorders. Maternal Fibrinogen level was reported to be within normal limits. The parents were not willing to do any further genetic work up. We believe that the presence of consanguinity favours the possibility of autosomal recessive inheritance, although a detailed genetic work up was not possible.
Administration of regular infusions of fibrinogen is recommended to maintain pregnancies in afibrinogenemic woman and to reduce the incidence of postpartum hemorrhage [16, 17]. Therapy should be initiated as early as possible because fetal loss in the first trimester is frequent. Fetal loss has occurred in some patients with fibrinogen levels above 50 mg/dL as well; therefore, it is recommended that levels be kept above 100 mg/dL through out the duration of the pregnancy.
Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of of the written consent is available for review by the Editor - in - Chief of this journal
- Leeners JV, Mossakowski J, Kayser S: Case report of congenital afibrinogenemia. Klin Pediatr. 1995, 207: 34-5. 10.1055/s-2008-1046506.View ArticleGoogle Scholar
- Corrigan JJ: 6th edition Blood diseases of infancy and childhood. Edited by: Miller DR, Bachner RL. 1990, St. Louis: C. V. Mosby Company, 866-Google Scholar
- Mannucci PM, Duga S, Peyvandi F: Recessively inherited coagulation disorders. Blood. 2004, 104: 1243-10.1182/blood-2004-02-0595.PubMedView ArticleGoogle Scholar
- Scott JP, Montgomery RR: Fibrinogen deficiency (Factor 1). Nelson Textbook of Pediatrics. Edited by: Behrman RE, Kliegman RM, Arvin AM. 2007, Philadelphia: W.B. Saunders Company, 2070-71. 18Google Scholar
- Maekawa H, Yamazumi K, Muramatsu S: An A alpha Ser-434 to Nglycosylated Asn substitution in a dysfibrinogen, fibrinogen Caracas II, characterized by impaired fibrin gel formation. J Biol Chem. 1991, 266: 11575-PubMedGoogle Scholar
- Hayes T: Dysfibrinogenemia and thrombosis. Arch Pathol Lab Med. 2002, 126: 1387-PubMedGoogle Scholar
- Hogan KA, Gorkun OV, Lounes KC: Recombinant fibrinogen Vlissingen/Frankfurt IV. The deletion of residues 319 and 320 from the gamma chain of fibrinogen alters calcium binding, fibrin polymerization, cross-linking, and platelet aggregation. J Biol Chem. 2000, 275: 17778-10.1074/jbc.M001618200.PubMedView ArticleGoogle Scholar
- Rosenberg JB, Newman PJ, Mosesson MW, Guillin MC, Amrani DL: Paris I dysfibrinogenemia: A point mutation in intron 8 results in insertion of a 15 amino acid sequence in the fibrinogen gamma-chain. Thromb Haemost. 1993, 69: 217-PubMedGoogle Scholar
- Menache D: Constitutional and familial disorders of fibrinogen. Thromb Haemost. 1964, 13: 172-Google Scholar
- Peyvandi F: Rare coagulation disorders. Haemophilia. 2004, 89: 25-Google Scholar
- Bolton-Maggs PH, Perry DJ, Chalmers EA: The rare coagulation disorders--Review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia. 2004, 10: 593-10.1111/j.1365-2516.2004.00944.x.PubMedView ArticleGoogle Scholar
- Rodriguez RC, Buchanar GR, Clanton MS: Prophylactic cryoprecipitate in congenital afibrinogenemia. Clin Pediatric. 1988, 207: 34-35.Google Scholar
- Collet JP, Soria J, Mirshahi M: Dusart syndrome: A new concept of the relationship between fibrin clot architecture and fibrin clot degradability: Hypofibrinolysis related to an abnormal clot structure. Blood. 1993, 82: 2462-PubMedGoogle Scholar
- Lijnen HR, Soria J, Soria C, Collen D, Caen JP: Dysfibrinogenemia (fibrinogen Dusard) associated with impaired fibrin-enhanced plasminogen activation. Thromb Haemost. 1984, 51: 108-PubMedGoogle Scholar
- Wada Y, Lord ST: A correlation between thrombotic disease and a specific fibrinogen abnormality (A alpha 554 Arg>Cys) in two unrelated kindred, Dusart and Chapel Hill III. Blood. 1994, 84: 3709-PubMedGoogle Scholar
- Sauls DL, Lockhart E, Warren ME, Lenkowski A, Wilhelm SE, Hoffman M: Modification of fibrinogen by homocysteine thiolactone increases resistance to fibrinolysis: A potential mechanism of the thrombotic tendency in hyperhomocysteinemia. Biochemistry. 2006, 45: 2480-10.1021/bi052076j.PubMedView ArticleGoogle Scholar
- Galanakis DK: Fibrinogen anomalies and disease. A clinical update. Hematol Clin North Am. 1992, 6: 1171-Google Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.